Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Steatohepatitis: A tale of two “hits”?

Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285

Autophagy regulates lipid metabolism

Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604

Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078

Triglyceride accumulation protects against fatty acid-induced lipotoxicity

Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827

Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese

Dixon, J. B., Bhathal, P. S., & O’Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,369

A lipidomic analysis of nonalcoholic fatty liver disease

Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338

Bitter melon extract attenuating hepatic steatosis may be mediated by FGF21 and AMPK/Sirt1 signaling in mice

Yu, Y., Zhang, X. H., Ebersole, B., Ribnicky, D., & Wang, Z. Q. (2013) · Scientific Reports · doi:10.1038/srep03142 · Cited by 46

Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr−/− mouse model

Kuba, M., Matsuzaka, T., Matsumori, R., Saito, R., Kaga, N., Taka, H., Ikehata, K., Okada, N., Kikuchi, T., Ohno, H., et al. (2015) · Scientific Reports · doi:10.1038/srep17604 · Cited by 46

Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage

Neuman, M. G., French, S. W., Zakhari, S., Malnick, S. D. H., Seitz, H. K., Cohen, L. B., Salaspuro, M. P., Voinea‐Griffin, A., Barasch, A., Kirpich, I., et al. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.01.003 · Cited by 44

Mapping the triglyceride distribution in NAFLD human liver by MALDI imaging mass spectrometry reveals molecular differences in micro and macro steatosis

Alamri, H., Patterson, N. H., Yang, E., Zoroquiaín, P., Lazaris, A., Chaurand, P., & Metrakos, P. P. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1506-8 · Cited by 44

Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update

Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 44

Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice

Konuma, K., Itoh, M., Suganami, T., Kanai, S., Nakagawa, N., Sakai, T., Kawano, H., Hara, M., Kojima, S., Izumi, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121528 · Cited by 43

Hepatic oleate regulates liver stress response partially through PGC-1α during high-carbohydrate feeding

Liu, X., Burhans, M. S., Flowers, M. T., & Ntambi, J. M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.001 · Cited by 44

Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model

Lee, A. Y., Lee, J. W., Kim, J., Mok, H. J., Park, S. J., Kim, S., Hong, S., Kim, J., Park, E., Kang, K., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.110 · Cited by 43

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment

Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 47

Loss of ULK1 increases RPS6KB1-NCOR1 repression of NR1H/LXR-mediated Scd1 transcription and augments lipotoxicity in hepatic cells

Sinha, R. A., Singh, B. K., Zhou, J., Xie, S. Y., Farah, B. L., Lesmana, R., Ohba, K., Tripathi, M., Ghosh, S., Hollenberg, A. N., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1235123 · Cited by 45

Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease

Pan, X., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002092 · Cited by 42

Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance

Jiang, Y., Zhao, M., & An, W. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0790-y · Cited by 42

Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges

Xiao, J., Guo, R., Fung, M., Liong, E. C., & Tipoe, G. L. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60021-1 · Cited by 44

The Association Between Hepatic Fat Content and Liver Injury in Obese Children and Adolescents

Santoro, N., Feldstein, A. E., Enoksson, E., Pierpont, B. M., Kursawe, R., Kim, G., & Caprio, S. (2012) · Diabetes Care · doi:10.2337/dc12-1791 · Cited by 42

Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease

Ciavarella, A., Gnocchi, D., Custodero, C., Lenato, G. M., Fiore, G., Sabbà, C., & Mazzocca, A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.002 · Cited by 43

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis

Rahman, K., Liu, Y., Kumar, P., Smith, T., Thorn, N. E., Farris, A. B., & Anania, F. A. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.61 · Cited by 39

G protein-coupled receptor 35 attenuates nonalcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes

Wei, X., Yin, F., Wu, M., Xie, Q., Zhao, X., Zhu, C., Xie, R.-Q., Chen, C., Liu, M., Wang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.011 · Cited by 41

Novel Pharmacotherapy Options for NASH

Ratziu, V. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4128-z · Cited by 43

Hypoxia‐inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36

Rey, E., Meléndez‐Rodríguez, F., Marañón, P., Gil‐Valle, M., García-Carrasco, A., Torres‐Capelli, M., Chavez, S., Pozo-Maroto, E. D., de Cía, J. R., Aragonés, J., et al. (2020) · Liver International · doi:10.1111/liv.14519 · Cited by 41

Liver cholesterol: is it playing possum in NASH?

Farrell, G. C., & Rooyen, D. M. V. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00008.2012 · Cited by 41

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40

Age and metabolic risk factors associated with oxidatively damaged DNA in human peripheral blood mononuclear cells

Løhr, M., Jensen, A., Eriksen, L., Grønbæk, M., Loft, S. H., & Möller, P. (2014) · Oncotarget · doi:10.18632/oncotarget.3202 · Cited by 40

Localisation of oxysterols at the sub-cellular level and in biological fluids

Dias, I. H. K., Borah, K., Amin, B., Griffiths, H. R., Sassi, K., Lizard, G., Iriondo, A., & Martínez‐Lage, P. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105426 · Cited by 40

Update on the synergistic effect of HSL and insulin in the treatment of metabolic disorders

Lan, Y., Lou, J., Lyu, W., & Zhang, B. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819877300 · Cited by 47

Plasma Lipidomics Reveals Insights into Anti-Obesity Effect of Chrysanthemum morifolium Ramat Leaves and Its Constituent Luteolin in High-Fat Diet-Induced Dyslipidemic Mice

Shon, J. C., Kim, W. C., Ryu, R., Wu, Z., Seo, J., Choi, M., & Liu, K. (2020) · Nutrients · doi:10.3390/nu12102973 · Cited by 40

Lipid Disorders in NAFLD and Chronic Kidney Disease

Yang, M., Geng, C., Liu, X., & Guan, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101405 · Cited by 44

Circulating lipidomic alterations in obese and non‐obese subjects with non‐alcoholic fatty liver disease

Jung, Y., Lee, M. K., Puri, P., Koo, B. K., Joo, S. K., Jang, S. Y., Lee, D. H., Jung, Y. J., Kim, B. G., Lee, K. L., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16066 · Cited by 39

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis

Le, T., & Loomba, R. S. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60104-2 · Cited by 41

Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome

Zimmermann, A., Zimmermann, T., Schattenberg, J. M., Pöttgen, S., Lotz, J., Rossmann, H., Roeddiger, R., Biesterfeld, S., Geiss, H. C., Schuchmann, M., et al. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.01.011 · Cited by 38

Non-alcoholic fatty liver disease: what's new under the microscope?

Brunt, E. M. (2011) · Gut · doi:10.1136/gut.2010.218214 · Cited by 38

Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis

Ratziu, V., Ghabril, M., Romero‐Gómez, M., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 40

Huang-Qi San improves glucose and lipid metabolism and exerts protective effects against hepatic steatosis in high fat diet-fed rats

Li, Y., Wang, C., Jin, Y., Chen, H., Cao, M., Li, W., Luo, H., & Wu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109734 · Cited by 40

A diet-induced Sprague–Dawley rat model of nonalcoholic steatohepatitis-related cirrhosis

Ichimura‐Shimizu, M., Masuzumi, M., Kawase, M., Sakaki, M., Tamaru, S., Nagata, Y., Tanaka, K., Suruga, K., Tsuneyama, K., Matsuda, S., et al. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.10.007 · Cited by 39

Steatosis in the Liver

Wang, D. Q. ‐., Portincasa, P., & Neuschwander‐Tetri, B. A. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130001 · Cited by 41

Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling

Seo, M. H., Lee, J., Hong, S.-W., Rhee, E.-J., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W., & Lee, W.-Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166913 · Cited by 37

Circular RNAs in human diseases

Wang, Y., Zhang, J., Yang, Y. S. H., Liu, Z., Sun, S., Li, R. F., Zhu, H., Tian, L., Zheng, J., Li, J., et al. (2024) · MedComm · doi:10.1002/mco2.699 · Cited by 41

Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy

Nagaya, T., Tanaka, N., Kimura, T., Kitabatake, H., Fujimori, N., Komatsu, M., Horiuchi, A., Yamaura, T., Umemura, T., Sano, K., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.02.001 · Cited by 37

The Role of Ceramide in the Pathogenesis of Alcoholic Liver Disease

Liu, Y., Jin, G., & Zhou, J. (2015) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv119 · Cited by 36

Metabolic insights from extreme human insulin resistance phenotypes

Stears, A. J., O’Rahilly, S., Semple, R. K., & Savage, D. B. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.003 · Cited by 38

Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose

Han, Y., Shi, J., Ma, A., Xu, Y., Ding, X., & Fan, J. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0136-3 · Cited by 37

CXCR4 dysfunction in non-alcoholic steatohepatitis in mice and patients

Boujedidi, H., Robert, O., Bignon, A., Cassard, A., Renoud, M.-L., Gary‐Gouy, H., Hémon, P., Tharinger, H., Prevot, S., Bachelerie, F., et al. (2014) · Clinical Science · doi:10.1042/cs20130833 · Cited by 35

Non-Alcoholic Fatty Liver Disease in Children: Focus on Nutritional Interventions

Yang, M., Gong, S., Ye, S. Q., Lyman, B., Geng, L., Chen, P., & Li, D. (2014) · Nutrients · doi:10.3390/nu6114691 · Cited by 36

A Protein Scaffold Coordinates SRC-Mediated JNK Activation in Response to Metabolic Stress

Kant, S., Standen, C. L., Morel, C., Jung, D. Y., Kim, J. K., Swat, W., Flavell, R. A., & Davis, R. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.025 · Cited by 37

Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High‐Fat Diet: Possible Role of the NLRP3 Inflammasome

Fantauzzi, C. B., Menini, S., Iacobini, C., Rossi, C., Santini, E., Solini, A., & Pugliese, G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8962458 · Cited by 36

LncRNA-AK012226 Is Involved in Fat Accumulation in db/db Mice Fatty Liver and Non-alcoholic Fatty Liver Disease Cell Model

Chen, X., Xu, Y., Zhao, D., Chen, T., Gu, C., Yu, G., Chen, K., Zhong, Y., He, J., Liu, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00888 · Cited by 36

Lipocalin‐2 Protects Against Diet‐Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes

Xu, Y., Zhu, Y., Jadhav, K. S., Li, Y., Sun, H., Yin, L., Kasumov, T., Chen, X., & Zhang, Y. (2019) · Hepatology Communications · doi:10.1002/hep4.1341 · Cited by 36

Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications

Xu, C., Li, H., & Tang, C. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155180 · Cited by 36

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

Shao, G., Liu, Y., Lu, L., Zhang, G., Zhou, W., Wu, T., Wang, L., Xu, H., & Ji, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944088 · Cited by 37

Folic Acid Supplementation Attenuates Chronic Hepatic Inflammation in High‐Fat Diet Fed Mice

Sid, V., Shang, Y., Siow, Y. L., Hewage, S. M., House, J. D., & Karmin, O. (2018) · Lipids · doi:10.1002/lipd.12084 · Cited by 35

Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease

Blencowe, M., Karunanayake, T., Wier, J. R., Hsu, N., & Yang, X. (2019) · Genes · doi:10.3390/genes10120966 · Cited by 36

Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro

Zhou, Z., Qi, J., Lim, C. W., Kim, J.-W., & Kim, B. (2020) · Toxicology · doi:10.1016/j.tox.2020.152579 · Cited by 36

Hypoxia and Non-alcoholic Fatty Liver Disease

Isaza, S. C., Pozo-Maroto, E. D., Domínguez-Alcón, L., Elbouayadi, L., González‐Rodríguez, Á., & García‐Monzón, C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.578001 · Cited by 35

Lipid-Lowering Effects of Inonotus obliquus Polysaccharide In Vivo and In Vitro

Yang, M., Hu, D., Cui, Z., Li, H., Man, C., & Jiang, Y. (2021) · Foods · doi:10.3390/foods10123085 · Cited by 35

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease

Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 36

Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease

Larter, C. Z., Yeh, M. M., Haigh, W. G., Rooyen, D. M. V., Brooling, J. T., Heydet, D., Nolan, C. J., Teoh, N., & Farrell, G. C. (2013) · Obesity · doi:10.1002/oby.20123 · Cited by 35

Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs

Zhao, Y. D., Zhao, W., Wang, H., Zhao, Y., Bu, H., & Takahashi, H. (2022) · Medicine · doi:10.1097/md.0000000000031508 · Cited by 34

Polymeric nanomedicines for the treatment of hepatic diseases

Luo, F., Yu, Y. F., Li, M., Chen, Y., Zhang, P., Xiao, C., & Lv, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01708-y · Cited by 35

Sesamin ameliorates lipotoxicity and lipid accumulation through the activation of the estrogen receptor alpha signaling pathway

Pham, T. H., Lee, G. H., Jin, S. W., Lee, S. Y., Han, E. H., Kim, N. D., Choi, C. Y., Jeong, G.-S., Lee, S. K., Kim, H. S., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115768 · Cited by 36

Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34

Lipids and Lysosomes

Hamer, I., Beersel, G. V., Arnould, T., & Jadot, M. (2012) · Current Drug Metabolism · doi:10.2174/138920012803762684 · Cited by 35

Fatty Liver Disease

TINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 35

Lipid phenotypes in patients with nonalcoholic fatty liver disease

Du, T., Sun, X., Yuan, G., Zhou, X., Lü, H., Lin, X., & Yu, X. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.006 · Cited by 34

Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus

Shigefuku, R., Takahashi, H., Nakano, H., Watanabe, T., Matsunaga, K., Matsumoto, N., Kato, M., Morita, R., Michikawa, Y., Tamura, T., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091545 · Cited by 34

Autofluorescence Spectroscopy for Monitoring Metabolism in Animal Cells and Tissues

Croce, A. C., & Bottiroli, G. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6788-9_2 · Cited by 34

Brown adipose tissue detected by PET/CT imaging is associated with less central obesity

Green, A. L., Bağcı, U., Hussein, S., Kelly, P. V., Muzaffar, R., Neuschwander‐Tetri, B. A., & Osman, M. (2017) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000691 · Cited by 34

Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis

Tomita, K., Kohli, R., MacLaurin, B. L., Hirsova, P., Guo, Q., Sanchez, L. H. G., Gelbard, H. A., Blaxall, B. C., & Ibrahim, S. H. (2017) · JCI Insight · doi:10.1172/jci.insight.94488 · Cited by 35

Gut microbiota mediated molecular events and therapy in liver diseases

Qi, X., Yang, M. J., Stenberg, J., Dey, R., Fogwe, L., Alam, M. S., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i48.7603 · Cited by 34

The Chromatin Remodeling Protein BRG1 Regulates SREBP Maturation by Activating SCAP Transcription in Hepatocytes

Kong, M., Zhu, Y., Shao, J., Fan, Z., & Xu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622866 · Cited by 34

Quercetin Attenuates High-Fat Diet-Induced Excessive Fat Deposition of Spotted Seabass (Lateolabrax maculatus) Through the Regulatory for Mitochondria and Endoplasmic Reticulum

Dong, Y., Xia, T., Lin, J., Wang, L., Song, K., & Zhang, C. (2021) · Frontiers in Marine Science · doi:10.3389/fmars.2021.746811 · Cited by 34

Interaction mechanisms between major depressive disorder and non-alcoholic fatty liver disease

Shao, Q., Wu, Y., Ji, J., Xu, T., Yu, Q., Ma, C., Liao, X., Cheng, F., & Wang, X. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.711835 · Cited by 32

Histone Modifications in NAFLD: Mechanisms and Potential Therapy

Shi, Y., & Qi, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914653 · Cited by 34

Pueraria lobata antioxidant extract ameliorates non-alcoholic fatty liver by altering hepatic fat accumulation and oxidative stress

Dong, H., Zhao, Y., Teng, H., Jiang, T. X., Yue, Y., Zhang, S., Fan, L., Yan, M., & Shao, S. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118468 · Cited by 33

The Role of CTGF in Liver Fibrosis Induced in 3D Human Liver Spheroids

Redenšek, S., van Riet, S., Nordling, Å., & Ingelman‐Sundberg, M. (2023) · Cells · doi:10.3390/cells12020302 · Cited by 33

The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease

Olveira, A., Augustín, S., Benlloch, S., Ampuero, J., Suárez‐Pérez, J. A., Armesto, S., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., et al. (2023) · Life · doi:10.3390/life13020419 · Cited by 38

Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications

Furuta, K., Tang, X., Islam, S., Tapia, A., Chen, Z. B., & Ibrahim, S. H. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108372 · Cited by 36

Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a β-oxidation defect

Tucci, S., Flögel, U., Sturm, M., Borsch, E., & Spiekerkoetter, U. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012948 · Cited by 33

Lipids in Liver Disease: Looking Beyond Steatosis

Schwabe, R. F., & Maher, J. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.11.004 · Cited by 33

Circulating fatty acids and risk of hepatocellular carcinoma and chronic liver disease mortality in the UK Biobank

Liu, Z., Huang, H., Xie, J., Xu, Y., & Xu, C. (2024) · Nature Communications · doi:10.1038/s41467-024-47960-8 · Cited by 32

The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study

Chen, Y., Yang, C., Chung, C., Ho, C., Chen, W., & Chien, W. (2022) · Hepatology International · doi:10.1007/s12072-021-10281-9 · Cited by 32

Ferroptosis: Shedding Light on Mechanisms and Therapeutic Opportunities in Liver Diseases

You, H., Wang, L., Bu, F., Meng, H., Huang, C., Fang, G.-Y., & Li, J. (2022) · Cells · doi:10.3390/cells11203301 · Cited by 33

Metabolomic signatures in lipid‐loaded HepaRGs reveal pathways involved in steatotic progression

Brown, M. V., Compton, S. A., Milburn, M. V., Lawton, K. A., & Cheatham, B. (2013) · Obesity · doi:10.1002/oby.20440 · Cited by 34

The Influence of an Obesogenic Diet on Oxysterol Metabolism in C57BL/6J Mice

Wooten, J. S., Wu, H., Raya, J. L., Perrard, X. D., Gaubatz, J. W., & Hoogeveen, R. C. (2014) · Cholesterol · doi:10.1155/2014/843468 · Cited by 32

Mitigation of Insulin Resistance by Mangiferin in a Rat Model of Fructose-Induced Metabolic Syndrome Is Associated with Modulation of CD36 Redistribution in the Skeletal Muscle

Zhou, L., Pan, Y., Chonan, R., Batey, R. G., Rong, X., YAMAHARA, J., Wang, J., & Li, Y. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229005 · Cited by 32

Plasma concentrations of zonulin are elevated in obese men with fatty liver disease

Kim, A., & Ko, H. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s163062 · Cited by 32

Oligonucleotide therapies for nonalcoholic steatohepatitis

Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 32

Improvement of Liquid Fructose-Induced Adipose Tissue Insulin Resistance by Ginger Treatment in Rats Is Associated with Suppression of Adipose Macrophage-Related Proinflammatory Cytokines

Wang, J., Gao, H., Ke, D., Zuo, G., Yang, Y., Yamahara, J., & Li, Y. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/590376 · Cited by 33

Circadian rhythms: a possible new player in non-alcoholic fatty liver disease pathophysiology

Gnocchi, D., Custodero, C., Sabbà, C., & Mazzocca, A. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01780-2 · Cited by 33

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma

Nardo, A. D., Grün, N. G., Zeyda, M., Dumanic, M., Oberhuber, G., Rivelles, E., Helbich, T. H., Markgraf, D. F., Roden, M., Claudel, T., et al. (2020) · Liver International · doi:10.1111/liv.14464 · Cited by 31

ALT Levels for Asians With Metabolic Diseases: A Meta‐analysis of 86 Studies With Individual Patient Data Validation

Huang, D. Q., Yeo, Y. H., Tan, E. X. X., Takahashi, H., Yasuda, S., Saruwatari, J., Tanaka, K., Oniki, K., Kam, L. Y., Muthiah, M. D., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1593 · Cited by 32

Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications

Ibrahim, S. H. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00009.2021 · Cited by 31

Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis

Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32

Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis

Fang, Q., Li, X., Wang, M., Qiao, X., Huang, F., Hu, C., Xue, Y., Zhao, S., & Lin, Y. (2022) · Food & Function · doi:10.1039/d2fo00012a · Cited by 31

Emerging functions of circular RNA in the regulation of adipocyte metabolism and obesity

Zhang, Y., Tian, Z., Ye, H., Sun, X., Zhang, H., Sun, Y., Mao, Y., Yang, Z., & Li, M. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01062-w · Cited by 33

5-Cholesten-3β,25-Diol 3-Sulfate Decreases Lipid Accumulation in Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model

Xu, L., Kim, J. K., Bai, Q., Zhang, X., Kakiyama, G., Min, H., Sanyal, A. J., Pandak, W. M., & Ren, S. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081505 · Cited by 31

Cholic Acid Enhances Visceral Adiposity, Atherosclerosis and Nonalcoholic Fatty Liver Disease in Microminipigs

Yamada, S., Kawaguchi, H., Yamada, T., Guo, X., Matsuo, K., Hamada, T., Miura, N., Tasaki, T., & Tanimoto, A. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.39909 · Cited by 31

Undaria pinnatifida fucoidan ameliorates dietary fiber deficiency-induced inflammation and lipid abnormality by modulating mucosal microbiota and protecting intestinal barrier integrity

Zheng, W., Jia, J., Zhang, C., Zhang, P., Song, S., & Ai, C. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125724 · Cited by 30

Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway

Desterke, C., & Chiappini, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225594 · Cited by 32

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals

Minami, T., Tateishi, R., Fujiwara, N., Nakagomi, R., Nakatsuka, T., Sato, M., Uchino, K., Enooku, K., Nakagawa, H., Fujinaga, H., et al. (2021) · Liver Cancer · doi:10.1159/000513705 · Cited by 31

Prevent and Reverse Metabolic Dysfunction-Associated Steatohepatitis and Hepatic Fibrosis via mRNA-Mediated Liver-Specific Antibody Therapy

Zhang, C., Teng, Y., Bai, X., Tang, M., Stewart, W., Chen, J., Xu, X., & Zhang, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c13404 · Cited by 36

Nontriglyceride Hepatic Lipotoxicity: The New Paradigm for the Pathogenesis of NASH

Neuschwander‐Tetri, B. A. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0083-6 · Cited by 64

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis

Branković, M., Jovanović, I., Dukić, M., Radonjić, T., Oprić, S., Klašnja, S., & Zdravkovic, M. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095146 · Cited by 72

Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients

Lawitz, E., Li, K. W., Nyangau, E., Field, T., Chuang, J.-C., Billin, A. N., Wang, L., Wang, Y., Huss, R. S., Chung, C., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100250 · Cited by 37

Steatosis in the Liver

Wang, D. Q. ‐., Portincasa, P., & Neuschwander‐Tetri, B. A. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130001 · Cited by 41

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis

Méndez‐Sánchez, N., Cruz-Ramón, V., Ramírez-Pérez, O., Hwang, J. P., Barranco-Fragoso, B., & Córdova‐Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 177